$PRPO News
Last published 1d ago
- 1d agoPRPOPrecipio, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoPRPOPrecipio Announces Q3-2026 Financial ResultsGlobeNewswireRecord quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth
- 2w agoPRPOPrecipio Announces Q3-2026 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2026 shareholder update call on November 10th, 2026, at 5:00 PM ET. The
- 2mo agoPRPOPrecipio Announces Q2-2026 Financial ResultsGlobeNewswireNEW HAVEN, Conn., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the second quarter that ended June 30, 2026. Below are some of
- 3mo agoPRPOPrecipio Announces Q2-2026 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call
- 5mo agoPRPOPrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingGlobeNewswireNEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares
- 5mo agoPRPOPrecipio to Present at the Planet MicroCap Las VegasGlobeNewswireNEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17,
- 6mo agoPRPOPrecipio Announces Q1 2026 Financial ResultsGlobeNewswireNEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key
- 6mo agoPRPOManagement team's 2025 market-based Options have vestedGlobeNewswireNEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team
- 6mo agoPRPOPrecipio Announces Q1-2026 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will
- 8mo agoPRPOPrecipio Announces Q4 and year-end 2025 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET.
- 8mo agoPRPOPrecipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 AssayGlobeNewswireNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in
- 8mo agoPRPOPrecipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-YearGlobeNewswireNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below
- 10mo agoPRPOPrecipio Takes Major Steps Toward a Clean Balance SheetGlobeNewswireNEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major
- 11mo agoPRPOPrecipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) MeetingGlobeNewswireNEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from
- 11mo agoPRPOPrecipio Identifies Unauthorized Access to Isolated Storage; No Operational ImpactGlobeNewswireNEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file
- 12mo agoPRPOPrecipio Announces its Q3-2025 Financial ResultsGlobeNewswireNEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial
- 1y agoPRPOPrecipio Announces Q3-2025 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2025 corporate update call on November 17th, 2025 at 5:00 PM ET. The call
- 1y agoPRPOPrecipio Terminates Its ATMGlobeNewswireNEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners
- 1y agoPRPOPrecipio, Inc. (PRPO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPRPOPrecipio Announces its Q2-2025 Financial ResultsGlobeNewswireNEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial
- 1y agoPRPOPrecipio Announces Q2-2025 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will
- 1y agoPRPOPrecipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As CashlessGlobeNewswireNEW HAVEN, Conn., July 11, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from
- 1y agoPRPOPrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingGlobeNewswireNEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares
- 1y agoPRPOPrecipio Announces its Q1-2025 Financial ResultsGlobeNewswireNEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance
- 1y agoPRPOPrecipio Announces Q1-2025 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2025 corporate update call on May 15th, 2025 at 5:00 PM ET. The call will
- 1y agoPRPOPrecipio Announces Q4 and year-end 2024 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2024 corporate update call on March 31st, 2025 at 5:00 PM ET.
- 1y agoPRPOPrecipio Achieves Key Q4-2024 Financial Goals: Positive Adjusted EBITDA and Positive Cash Flow (unaudited)GlobeNewswireNEW HAVEN, Conn., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it has achieved two important financial goals in the last quarter of 2024:
- 1y agoPRPOPrecipio grants senior management performance-based awards instead of traditional time-vested ESOPsGlobeNewswireNEW HAVEN, Conn., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced that options granted to senior management on January 14 would vest when the 10-day VWAP
- 1y agoPRPOPrecipio, Inc. (PRPO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPRPOPrecipio Announces Q3-2024 Shareholder Update CallGlobeNewswireConference Call to be held on November 18, 2024, at 5:00 PM EST NEW HAVEN, Conn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2024
- 2y agoPRPOPrecipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation SubtypingGlobeNewswireNEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that
- 2y agoPRPOPrecipio Announces Employee Stock Option Plan RepricingGlobeNewswireNEW HAVEN, Conn., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces the Company's repricing of a portion of its employee stock options to ensure their
- 2y agoPRPOPrecipio, Inc. (PRPO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPRPOPrecipio Announces Q2-2024 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2024 corporate update call on August 19th at 5:00 PM ET. The call will
- 2y agoPRPOPrecipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakevenGlobeNewswireNEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was
- 2y agoPRPOPrecipio Reports $4.4M for Q2-2024 (unaudited) Revenues, a leap of 30% from Q1-2024GlobeNewswireNEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in
- 2y agoPRPOPrecipio Inc. Announces Adjournment of Annual Meeting of StockholdersGlobeNewswireNEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that the company's 2024 Annual Meeting of Shareholders ("Annual Meeting") was convened and
- 2y agoPRPOPrecipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders MeetingGlobeNewswireNEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares
- 2y agoPRPOPrecipio Provides Status Update on Current Business MattersGlobeNewswireNEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) provides the following update to its shareholders on various business matters looking
- 2y agoPRPOPrecipio Secures a short-term $500K Credit FacilityGlobeNewswireNEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash
- 2y agoPRPOPrecipio Announces Year end 2023 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call
- 2y agoPRPOPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewswireNEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to
- 2y agoPRPOPrecipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewswireNEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen
- 2y agoPRPOPrecipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterGlobeNewswireNEW HAVEN, Conn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that continued revenue growth generated cash levels that bring the company closer to
- 2y agoPRPOPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanGlobeNewswireNEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and
- 2y agoPRPOPrecipio Announces Christina Valauri joins the Board of DirectorsGlobeNewswireNEW HAVEN, Conn., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is pleased to welcome Christina Valauri to its board of directors effective Jan 1st, 2024. Ms.
- 2y agoPRPOPrecipio Management Shares Thoughts on 2023, and Looks Ahead To 2024GlobeNewswireNEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) shares thoughts and reflections looking back at 2023, and forward to 2024. At the
- 2y agoPRPOPrecipio, Inc. (PRPO) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPRPOPrecipio Announces Q3-2023 Shareholder Update CallGlobeNewswireNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call